Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations.

The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.

Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis.

Clinical pharmacokinetics of epoetin (recombinant human erythropoietin).

Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects.

Self-administered daily subcutaneous recombinant human erythropoietin: an open randomised dose-finding study in ESRD patients receiving peritoneal dialysis.

Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats.

Use of recombinant erythropoietin in thalassemic patients on dialysis.

Adverse events of subcutaneous recombinant human erythropoietin therapy.

Exercise in hemodialysis patients after treatment with recombinant human erythropoietin.

Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: comparison between intravenous and subcutaneous administration.

The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients.

Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients.

Serum erythropoietin levels in hemodialysed patients after administration of recombinant human erythropoietin.

A comparison of the pharmacokinetics of multiple and single dose administrations of adriamycin.

Low-dose recombinant human erythropoietin in dialysis patients living at high altitude.

Recombinant human erythropoietin reduces free erythrocyte protoporphyrin levels in patients on chronic dialysis.

Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations.

Pharmacokinetics of sulpiride in humans after intravenous and intramuscular administrations.

Dialysis patients with the metabolic syndrome need less recombinant human erythropoietin for similar hemoglobin levels.

Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers.

Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease.

Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment.

Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin.

Effect of recombinant human erythropoietin treatment on hemodynamic parameters in continuous ambulatory peritoneal dialysis and hemodialysis patients.

Suggest Documents

The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.

Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis.

Clinical pharmacokinetics of epoetin (recombinant human erythropoietin).

Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects.

Self-administered daily subcutaneous recombinant human erythropoietin: an open randomised dose-finding study in ESRD patients receiving peritoneal dialysis.

Pharmacokinetics of PEGylated Recombinant Human Erythropoietin in Rats.

Use of recombinant erythropoietin in thalassemic patients on dialysis.

Adverse events of subcutaneous recombinant human erythropoietin therapy.

Exercise in hemodialysis patients after treatment with recombinant human erythropoietin.

Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: comparison between intravenous and subcutaneous administration.

The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients.

Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients.

Serum erythropoietin levels in hemodialysed patients after administration of recombinant human erythropoietin.

A comparison of the pharmacokinetics of multiple and single dose administrations of adriamycin.

Low-dose recombinant human erythropoietin in dialysis patients living at high altitude.

Recombinant human erythropoietin reduces free erythrocyte protoporphyrin levels in patients on chronic dialysis.

Population pharmacokinetic modeling of LY2189102 after multiple intravenous and subcutaneous administrations.

Pharmacokinetics of sulpiride in humans after intravenous and intramuscular administrations.

Dialysis patients with the metabolic syndrome need less recombinant human erythropoietin for similar hemoglobin levels.

Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers.

Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease.

Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment.

Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin.

Effect of recombinant human erythropoietin treatment on hemodynamic parameters in continuous ambulatory peritoneal dialysis and hemodialysis patients.

Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations.

Recommend Documents

Follow Us